Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported an equity award vesting and share issuance. On 11/17/2025, 232 restricted stock units converted into 232 shares of common stock at an exercise price of $0, increasing his directly held common stock to 1,047 shares.
The transaction reflects ongoing vesting from a restricted stock unit grant awarded on July 17, 2024. That grant vests over four years, with 25% of the shares vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting in equal monthly installments over the following three years. After this conversion, he continues to hold 7,425 restricted stock units directly.
Guardant Health, Inc. (GH)Common Stock were acquired at a price of $0, following the vesting and settlement of a previously granted restricted stock unit award. After this transaction, Tariq beneficially owned 7,975 shares of Common Stock directly and held 3,998 restricted stock units directly.
The restricted stock units were granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health (GH) reported insider activity by director Manuel Hidalgo Medina. On 11/07/2025, he exercised 1,000 stock options at $32.55 and sold 1,500 shares in two trades at $95.1651 and $95.2301. Following these transactions, he held 815 shares directly.
The exercised option was granted on July 17, 2024 and expires on July 17, 2034. Per the award’s terms, 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years. After these transactions, he reported 16,029 derivative securities (stock options) beneficially owned.
Guardant Health (GH) reported an insider transaction by its Chief Legal Officer. On 11/07/2025, the reporting person sold 8,996 shares of common stock at a price of $96.25 per share. Following the sale, the filing shows 43,172 shares beneficially owned, held directly.
Guardant Health completed two financings. It sold 3,833,332 shares of common stock at $90.00 per share, including the full 499,999-share option, for net proceeds of approximately $327.2 million after underwriting discounts and expenses. The equity sale was made off an effective shelf and closed on November 7, 2025.
Separately, the company issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due May 15, 2033, including the full $52.5 million option. Net proceeds were approximately $390.0 million. The notes carry no regular interest, are unsecured, and are convertible at an initial rate of 8.2305 shares per $1,000 (initial conversion price about $121.50 per share), a premium of about
Guardant Health (GH) is offering 3,333,333 shares of common stock at $90.00 per share, for estimated net proceeds of about $284.4 million after fees and expenses. The underwriters have a 30‑day option to buy up to 499,999 additional shares. Shares outstanding are expected to be 128,339,048 immediately after this offering (or 128,839,047 if the option is fully exercised).
Concurrently, the company is offering 0% Convertible Senior Notes due 2033 in an aggregate principal amount of $350.0 million (or $402.5 million if the option is exercised) in a separate, exempt offering; neither transaction is contingent on the other. Guardant plans to use equity and, if completed, note proceeds for general corporate purposes, which may include repurchasing a portion of its 2027 notes.
The stock trades on Nasdaq as “GH”; the last reported sale price on November 4, 2025 was $98.14. Settlement is expected on or about November 7, 2025 (T+2).
Guardant Health (GH) is offering $250.0 million of common stock under a prospectus supplement. Assuming a public offering price of $98.92 per share (the last reported sale price on November 3, 2025), the company would offer approximately 3,032,753 shares. The underwriters have a 30‑day option to purchase up to an additional $37.5 million of shares.
Concurrently, Guardant is offering Convertible Senior Notes due 2033 in an aggregate principal amount of $300.0 million (or $345.0 million if the option is exercised in full) to QIBs in a separate, exempt offering; neither transaction is contingent on the other. The company intends to use net proceeds from this equity offering, together with any proceeds from the notes offering if consummated, for general corporate purposes, which may include repurchasing a portion of its 0% convertible senior notes due 2027.
Shares outstanding were 125,005,715 as of September 30, 2025. The filing highlights dilution risk to new purchasers and notes a company lock-up period of 60 days.
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.
The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.
Guardant Health (GH) filed its Q3 2025 10-Q, reporting higher revenue and a narrower loss. Revenue rose to $265,196,000 from $191,476,000 a year ago, while net loss improved to $92,725,000 from $107,754,000. Loss per share was $0.74 versus $0.88.
Growth was broad-based: Oncology revenue was $184,402,000, Biopharma and data $54,731,000, Screening $24,112,000, and Licensing and other $1,951,000. For the nine months, revenue totaled $700,755,000, with a net loss of $287,783,000.
Cash and cash equivalents were $580,013,000, with restricted cash of $109,502,000; total assets were $1,276,786,000. Operating cash outflow for the nine months was $158,387,000. The company exchanged $659,300,000 of 2027 notes for $600,000,000 of 1.25% notes due 2031, recording a $13,672,000 gain and leaving $490,700,000 of 2027 notes outstanding. Treasury stock repurchases were $45,010,000 for 976,351 shares. As of October 24, 2025, 126,041,089 common shares were outstanding.
Guardant Health, Inc. furnished an update on its latest results by submitting a Form 8-K. On October 29, 2025, the company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025, and attached the full text of that release as Exhibit 99.1. The disclosure clarifies that this information, including the exhibit, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.